<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150810</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-290-103</org_study_id>
    <secondary_id>2017-001553-14</secondary_id>
    <nct_id>NCT03150810</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Myriad Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety and tolerability of pamiparib,&#xD;
      the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined&#xD;
      with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in&#xD;
      combination with TMZ, and to determine the antitumor activity of pamiparib in combination&#xD;
      with TMZ.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE.</measure>
    <time_frame>From first dose BGB-290 and TMZ to 28 days post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs)</measure>
    <time_frame>From first dose BGB-290 and TMZ to 30 days post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing Severe Adverse Events (SAEs)</measure>
    <time_frame>From first dose BGB-290 and TMZ to 30 days post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From first dose BGB-290 and TMZ to first documentation of disease progression, assessed up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum observed plasma concentration (Cmax) of BGB-290 and TMZ.</measure>
    <time_frame>From first dose BGB-290 and TMZ to 30 days post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lowest concentration reached before the next dose administered (Ctrough) of BGB-290 and TMZ.</measure>
    <time_frame>From first dose BGB-290 and TMZ to 30 days post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach maximum (peak) plasma concentration (Tmax) of BGB-290 and TMZ.</measure>
    <time_frame>From first dose BGB-290 and TMZ to 30 days post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR).</measure>
    <time_frame>From first dose BGB-290 and TMZ to first documentation of disease progression, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From first dose BGB-290 and TMZ to first documentation of disease progression while participant is alive, assessed to up 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From first dose BGB-290 and TMZ to first documentation of disease progression or death, whichever is first, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose BGB-290 and TMZ until date of death, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Locally Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A (Dose Escalation) TMZ Pulse Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 7 of a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Dose Escalation) TMZ Continuous Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 28 of a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion, 6 cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive continuous BGB-290 and TMZ at the recommended phase 2 dose (RP2D) and schedule in 28 day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamiparib</intervention_name>
    <description>60 mg (20 mg capsules) administered orally twice a day</description>
    <arm_group_label>Arm A (Dose Escalation) TMZ Pulse Dosing</arm_group_label>
    <arm_group_label>Arm B (Dose Escalation) TMZ Continuous Dosing</arm_group_label>
    <arm_group_label>Dose Expansion, 6 cohorts</arm_group_label>
    <other_name>BGB-290</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Doses of up to 120 mg (as 20 mg capsules) administered orally once daily (QD) as specified in the treatment arm</description>
    <arm_group_label>Arm A (Dose Escalation) TMZ Pulse Dosing</arm_group_label>
    <arm_group_label>Arm B (Dose Escalation) TMZ Continuous Dosing</arm_group_label>
    <arm_group_label>Dose Expansion, 6 cohorts</arm_group_label>
    <other_name>TMZ</other_name>
    <other_name>temodar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years old with advanced or metastatic stage solid tumors&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) status ≤ 1 and measurable disease per RECIST&#xD;
             V1.1 (except for participants in dose escalation and prostate cancer participants)&#xD;
&#xD;
          3. Additional inclusion criteria for dose expansion cohorts:&#xD;
&#xD;
        Participants with homologous recombination deficiency (HRD+) or known BRCA mutant Ovarian&#xD;
        cancer&#xD;
&#xD;
        a. Previously received at least 1 line of platinum containing chemotherapy and No&#xD;
        progression or recurrent disease in 6 months from last platinum containing regimen.&#xD;
        Participants with HRD+ or known breast cancer susceptibility gene (BRCA) mutant&#xD;
        Triple-Negative Breast Cancer&#xD;
&#xD;
        a. 0 - 1 prior platinum-containing regimen (any treatment setting) and received ≤ 3 prior&#xD;
        regimens (advanced or metastatic setting).&#xD;
&#xD;
        Participants with HRD+ or known BRCA mutant Prostate cancer&#xD;
&#xD;
          1. Chemotherapy-naïve or previously received ≤2 taxane-based regimens.&#xD;
&#xD;
          2. May have pre-or post-treatment with a novel androgen receptor targeted agent.&#xD;
             Participants Small cell lung and gastric cancer&#xD;
&#xD;
        a. Previously received ≤ 2 prior lines of therapy. Participants with HRD+ NSCLC, head and&#xD;
        neck cancer, esophageal cancer and soft tissue sarcomas&#xD;
&#xD;
          1. Must have tumors with with HRD+ as centrally determined&#xD;
&#xD;
          2. Must have received at least 1 but not more than 3 prior lines of therapy.&#xD;
&#xD;
        Treatment naïve patients with soft tissue sarcoma might be allowed if standard of care&#xD;
        therapy is not suitable or available.&#xD;
&#xD;
        Key Exclusion Criteria: All participants&#xD;
&#xD;
          1. Prior exposure to a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor.&#xD;
&#xD;
          2. Refractory to platinum-based therapy.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maggie Zhang</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1 (877) 828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai - PRIME</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center PRIME</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (Tennessee Oncology)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas- MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre Wesley</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre Chermside</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre North Lakes</name>
      <address>
        <city>North Lakes</city>
        <state>Queensland</state>
        <zip>4509</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre South Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre Southport</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catalia d'oncologia- l'Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid-Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START-Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Cancer Trials Research Centre</name>
      <address>
        <city>Newcastle</city>
        <state>Newcastle Upon Tyne</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Small cell lung cancer</keyword>
  <keyword>Prostate cancer,</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>temozolomide</keyword>
  <keyword>BGB-290</keyword>
  <keyword>antineoplastic agents</keyword>
  <keyword>alkylating, alkylating agents,</keyword>
  <keyword>Poly (ADP-ribose) polymerase inhibitors</keyword>
  <keyword>enzyme inhibitors</keyword>
  <keyword>Head and neck cancer</keyword>
  <keyword>Esophageal cancer</keyword>
  <keyword>Soft tissue sarcoma</keyword>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>pamiparib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

